Helix BioPharma discovers, develops, and seeks licensing for pharmaceuticals to prevent and treat cancer. The company's drug candidates include treatments for female conditions such as human papillomavirus (HPV), a precursor to cervical cancer; common forms of lung cancer such as andenocarcinoma; and potential therapies for breast and prostate cancers. To help fund its drug discovery operations, Helix BioPharma distributes pharmaceuticals and other products for conditions such as gastrointestinal, orthopedic, and immune system disorders in Canada through subsidiary Rivex Pharma.

Provectus Pharmaceuticals, Inc. company was founded in 2002 and is based in Knoxville, Tennessee. Provectus Pharmaceuticals, Inc., a development stage company, specializes in oncology and dermatology therapies. The company is conducting Phase II clinical trials of its proprietary drugs PV-10 as a therapy for metastatic melanoma, and PH-10 as a topical treatment for psoriasis and atopic dermatitis. It received orphan drug designation from the FDA for its melanoma indication. In addition to its suite of proprietary drugs, Provectus Pharmaceuticals developed various intellectual properties and technologies in the areas of imaging, medical devices, and biotechnology.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

Panacea Pharmaceuticals, Inc. was founded in 1999 and is based in Gaithersburg, Maryland. Panacea Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic and diagnostic products for cancer and diseases of the central nervous system. It focuses on the development of proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology, as well as neurodegenerative diseases such as stroke, Alzheimer's disease, and Parkinson's disease. The company’s products include PAN-22, a human anit-HAAH monoclonal antibody for treatment of hepatocellular carcinoma; PAN-622, a Toxin Conjugate to treat carcinoma of the bile duct; and PAN-811 for the treatment of ischemic stroke. In addition, it develops blood, serum, and tissue tests to diagnose and monitor breast, colorectal, lung, and prostate cancers, as well as gene expression test that predicts the response of patients with Chronic Myelogenous Leukemia to imatinib.

Bio-Botanica was founded in 1972 by CEO Frank D'Amelio. Bio-Botanica Inc. company develops and manufactures a variety of botanical extracts used by customers throughout the US and internationally, in the nutraceutical, food and beverage, and cosmetics industries. Bio-Botanica's more than 300 extracts come in solid, semi-solid, powdered, and liquid forms and are used as both active ingredients and preservatives in products ranging from teas to soaps and homeopathic remedies. The company also produces its own line of consumer products, including extracts and blended nutritional supplements, which are sold through retailers under the Nature's Answer brand.

The Government Pharmaceutical Organization (GPO) provides the medicine that keeps Thai residents healthy. The organization researches and manufactures a wide variety of pharmaceutical products for ailments involving the respiratory, cardiovascular, and gastrointestinal systems, and vaccines, among others. GPO also makes vitamins, supplements, and diagnostic test kits. The organization's more than hundreds of pharmacists offer services through its about a dozen facilities, including retail drug stores. The Government Pharmaceutical Laboratories and the Division of Medical Depot merged to form GPO in 1966. The organization is part of Thailand's Ministry of Public Health.

Genmab was founded in 1999. Genmab analyzes genomes in its lab. The biotech company creates and develops human antibodies to treat such conditions as lymphoma and other cancers, as well as autoimmune and inflammatory diseases. It has assembled a portfolio of products under its HuMax brand that are in different stages of development, ranging from pre-clinical to late-stage trials. In addition to developing its HuMax products, Genmab is working to create products for conditions such as infectious diseases and vascular conditions. The company has licensing and development partnerships with several international pharmaceutical and biotech companies including GlaxoSmithKline, Amgen, Medarex, and Roche.

Discovery Laboratories was founded in 1992 and is headquartered in Warrington, Pennsylvania. Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. The company's proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Its products include Surfaxin, a synthetic, peptide-containing surfactant for use in pediatric medicine; Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants; and Aerosurf, which is a KL4 Surfactant in aerosolized form to treat premature infants at risk for RDS. Discovery Laboratories also focuses on the development of Surfaxin to address bronchopulmonary dysplasia in premature infants, acute respiratory failure in children, cystic fibrosis, acute lung injury, and other diseases associated with the inflammation of the lung, such as asthma and chronic obstructive pulmonary disease. The company has a license agreement with Philip Morris USA Inc. to use its Capillary Aerosolization Technology for use with pulmonary surfactants for the respiratory diseases; and has a strategic alliance with Laboratorios del Dr. Esteve, S.A. to develop, market, and sell surfactant products in Andorra, Greece, Italy, Portugal, and Spain.

Sangamo BioSciences, Inc. was founded in 1995 and is based in Richmond, California. Sangamo BioSciences, Inc. engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs can be engineered to make ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off; and ZFP nucleases, proteins that enable to modify DNA sequences in various ways. The company’s ZFP Therapeutic, SB-509, a plasmid formulation of a ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene, which is in three Phase 2 clinical trials for the treatment of diabetic neuropathy and one Phase 2 trial for amyotrophic lateral sclerosis. It also develops SB-728-T, which is in the Phase 1 clinical trial for the treatment of HIV/AIDS. In addition, Sangamo BioSciences, Inc. involves in the preclinical development programs of ZFP therapeutics that focus on spinal cord injury, stroke, traumatic brain injury, neuropathic pain, and Parkinson's disease. Additionally, the company has research-stage programs in X-linked severe combined immunodeficiency, hemophilia, and hemoglobinopathies. It has license agreements with companies, including Dow AgroSciences, LLC;Sigma-Aldrich Corporation; Pfizer, Inc.; Genentech Inc.; and Medarex, Inc., as well as has research agreements with Amgen Inc., Novo Nordisk Inc., Novartis A/G, and Kirin Brewery Company.

Ondine Biopharma wants to offer an alternative to antibiotics for treating infections. The company is focused on the development and commercialization of its patented light-activated technology, called photodynamic disinfection, as a therapy for bacterial, fungal, and viral infections. Ondine Biopharma is developing a nasal system called MRSAid that incorporates hardware and photosensitizers to help treat often deadly hospital-acquired pathogens, such as staph infections. If commercialized, that product would give the company entry into the hospital infection control market.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.